AbbVie Price To Operating Cash Flows Ratio from 2010 to 2024

ABBV Stock  USD 171.09  3.34  1.91%   
AbbVie Price To Operating Cash Flows Ratio yearly trend continues to be fairly stable with very little volatility. Price To Operating Cash Flows Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, AbbVie Price To Operating Cash Flows Ratio regression line of quarterly data had mean square error of  27.04 and geometric mean of  12.19. View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
11.99645168
Current Value
13.89
Quarterly Volatility
5.02378755
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 B, Interest Expense of 1.1 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of AbbVie Inc over the last few years. It is AbbVie's Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Very volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

AbbVie Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean12.80
Geometric Mean12.19
Coefficient Of Variation39.24
Mean Deviation3.01
Median11.47
Standard Deviation5.02
Sample Variance25.24
Range20.92
R-Value(0.07)
Mean Square Error27.04
R-Squared0.01
Significance0.80
Slope(0.08)
Total Sum of Squares353.34

AbbVie Price To Operating Cash Flows Ratio History

2024 13.89
2023 12.0
2022 11.47
2021 10.52
2020 10.16
2019 9.84
2018 10.58

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio 12.00  13.89 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.